Ceftaroline: Clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA

Diagnostic Microbiology and Infectious Disease

Volumn 81, Issue 3, 2015, Pages 183-188

  Stryjewski, Martin E ^a   Jones, Ronald N ^b   Corey, G Ralph ^c,d  

^a CEMIC   (Argentina)

^b JMI LABORATORIES   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Ceftaroline; Clinical experience; MRSA; Post market surveillance

Indexed keywords

CEFTAROLINE FOSAMIL; ANTIINFECTIVE AGENT; CEFTAROLINE; CEPHALOSPORIN DERIVATIVE;

ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL PNEUMONIA; BACTERIUM ISOLATE; BLOOD CLOTTING DISORDER; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED BACTERIAL PNEUMONIA; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; IN VITRO STUDY; INFECTIOUS ARTHRITIS; INTERSTITIAL NEPHRITIS; LOEFFLER PNEUMONIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); NEUTROPENIA; NONHUMAN; OFF LABEL DRUG USE; OSTEOMYELITIS; PHASE 4 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PURPURIC RASH; SKIN INFECTION; SURGICAL INFECTION; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; COMMUNITY-ACQUIRED INFECTIONS; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; DRUG APPROVAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PRODUCT SURVEILLANCE, POSTMARKETING; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; UNITED STATES;

EID: 84925126279     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2014.11.016     Document Type: Article

References (47)

1. Baines S.D., Chilton C.H., Crowther G.S., Todhunter S.L., Freeman J., Wilcox M.H. Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model. J Antimicrob Chemother 2013, 68:1842-1849.
2. Bohm N.M., Crosby B. Hemarthrosis in a patient on warfarin receiving ceftaroline: a case report and brief review of cephalosporin interactions with warfarin. Ann Pharmacother 2012, 46:e19.
3. Casapao A.M., Barber K.E., Wong C.K., Barr V., Steinke L.M., Mynatt R.P., et al. Clinical experience with ceftaroline fosamil for bloodstream infections. 23rd European Congress of Clinical Microbiology and Infectious Diseases; P858; Berlin 2013.
4. Casapao A.M., Davis S.L., Barr V.O., Klinker K.P., Goff D.A., Barber K.E., et al. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother 2014, 58:2541-2546.
5. Clinical and Laboratory Standards Institute (CLSI) M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 2012, CLSI, Wayne, PA. 9th ed.
6. Clinical and Laboratory Standards Institute (CLSI) M100-S24. Performance standards for antimicrobial susceptibility testing: 24th informational supplement 2014, CLSI, Wayne, PA.
7. Cole P., Udeani G., Smith A., Jandourek A., Friedland H.D. Ceftaroline fosamil for the treatment of infected surgical wounds: experience from the CAPTURE Study. 33rd Annual Meeting of the Surgical Infection Society; P-17; Las Vegas 2013.
8. Corey G.R., Wilcox M., Talbot G.H., Friedland H.D., Baculik T., Witherell G.W., et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010, 51:641-650.
9. Corey G.R., Wilcox M.H., Talbot G.H., Thye D., Friedland D., Baculik T. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010, 65(Suppl. 4):iv41-iv51.
10. Desai K.R., Burdette S.D., Polenakovik H.M., Hagaman J., Pleiman C.M. Ceftaroline-induced eosinophilic pneumonia. Pharmacotherapy 2013, 33:e166-e169.
11. Farrell D.J., Castanheira M., Mendes R.E., Sader H.S., Jones R.N. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). Clin Infect Dis 2012, 55(Suppl. 3):S206-S214.
12. Farrell D.J., Flamm R.K., Jones R.N., Sader H.S. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). Diagn Microbiol Infect Dis 2013, 75:86-88.
13. File T.M., Low D.E., Eckburg P.B., Talbot G.H., Friedland H.D., Lee J., et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010, 51:1395-1405.
14. File T.M., Low D.E., Eckburg P.B., Talbot G.H., Friedland H.D., Lee J., et al. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011, 66(Suppl. 3):iii19-iii32.
15. Flamm R.K., Sader H.S., Farrell D.J., Jones R.N. Ceftaroline potency among 9 US Census regions: report from the 2010 AWARE Program. Clin Infect Dis 2012, 55(Suppl. 3):S194-S205.
16. Flamm R.K., Sader H.S., Farrell D.J., Jones R.N. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program. Antimicrob Agents Chemother 2012, 56:2933-2940.
17. Flamm R.K., Sader H.S., Jones R.N. Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: Results from the AWARE Program, 2009-2011. Diagn Microbiol Infect Dis 2014, 78:437-442.
18. Frampton J.E. Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia. Drugs 2013, 73:1067-1094.
19. Griffiths C.L., Gutierrez K.C., Pitt R.D., Lovell R.D. Eosinophilic pneumonia induced by ceftaroline. Am J Health Syst Pharm 2014, 71:403-406.
20. Ho T.T., Cadena J., Childs L.M., Gonzalez-Velez M., Lewis J.S. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother 2012, 67:1267-1270.
21. Jacqueline C., Amador G., Caillon J., Le Mabecque V., Batard E., Miegeville A.F., et al. Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. J Antimicrob Chemother 2010, 65:1749-1752.
22. Jandourek A., Cunningham A., Udeani G., Li Y., Friedland D. Community-acquired bacterial pneumonia (CABP) due to methicillin-resistant Staphylococcus aureus (MRSA) and treatment with ceftaroline fosamil: experience from the CAPTURE Study. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy September; L1-300c; San Francisco 2012.
23. Jandourek A., Udeani G., Smith A., Friedland H.D. CAPTURE Study experience in patients with community acquired pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA) and treatment with ceftaroline. 23rd European Congress of Clinical Microbiology and Infectious Diseases;P-841; Berlin 2013.
24. Jones R.N., Flamm R.K., Sader H.S., Stilwell M.G. Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically-indicated species. Diagn Microbiol Infect Dis 2013, 75:89-93.
25. Jones R.N., Sader H.S., Mendes R.E., Flamm R.K. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). Diagn Microbiol Infect Dis 2013, 75:107-109.
26. Jongsma K., Joson J., Heidari A. Ceftaroline in the treatment of concomitant methicillin-resistant and daptomycin-non-susceptible Staphylococcus aureus infective endocarditis and osteomyelitis: case report. J Antimicrob Chemother 2013, 68:1444-1445.
27. Lin J.C., Aung G., Thomas A., Jahng M., Johns S., Fierer J. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother 2013, 19:42-49.
28. Lodise T.P., Low D.E. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Drugs 2012, 72:1473-1493.
29. Low D.E., File T.M., Eckburg P.B., Talbot G.H., David Friedland H., Lee J., et al. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011, 66(Suppl. 3):iii33-iii44.
30. MacGowan A.P., Noel A.R., Tomaselli S., Bowker K.E. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother 2013, 57:2451-2456.
31. Melard A., Garcia L.G., Das D., Rozenberg R., Tulkens P.M., Van Bambeke F., et al. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin. J Antimicrob Chemother 2013, 68:648-658.
32. Mendes R.E., Tsakris A., Sader H.S., Jones R.N., Biek D., McGhee P., et al. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. J Antimicrob Chemother 2012, 67:1321-1324.
33. Najjar S., Biehle L., Najjar J., Finkel D. Treatment of methicillin-resistant Staphylococcus aureus bacteremia and prosthetic valve endocarditis with ceftaroline. Infect Dis Clin Pract 2014, 22:108-109.
34. Panagiotidis G., Backstrom T., Asker-Hagelberg C., Jandourek A., Weintraub A., Nord C.E. Effect of ceftaroline on normal human intestinal microflora. Antimicrob Agents Chemother 2010, 54:1811-1814.
35. Pfaller M.A., Flamm R.K., Sader H.S., Jones R.N. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011). Diagn Microbiol Infect Dis 2014, 78:422-428.
36. Polenakovik H.M., Pleiman C.M. Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature. Int J Antimicrob Agents 2013, 42:450-455.
37. Rimawi R.H., Frenkel A., Cook P.P. Ceftaroline-a cause for neutropenia. J Clin Pharm Ther 2013, 38:330-332.
38. Rose W.E., Schulz L.T., Andes D., Striker R., Berti A.D., Hutson P.R., et al. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother 2012, 56:5296-5302.
39. Sader H.S., Flamm R.K., Jones R.N. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010). Diagn Microbiol Infect Dis 2013, 76:61-68.
40. Sakoulas G., Nonejuie P., Nizet V., Pogliano J., Crum-Cianflone N., Haddad F. Treatment of high-level gentamicin-resistant Enterococcus faecalis endocarditis with daptomycin plus ceftaroline. Antimicrob Agents Chemother 2013, 57:4042-4045.
41. Santos P.D., Davis A., Jandourek A., Smith A., Friedland H.D. Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience. J Chemother 2013, 25:341-346.
42. Saravolatz L., Pawlak J., Johnson L. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob Agents Chemother 2010, 54:3027-3030.
43. Teflaro® Package Insert 2012, Forest Laboratories, Inc., New York City, NY.
44. Udeani G., Evans J., Jandourek A., Friedland H.D. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia (CABP): CAPTURE Year 1. American Thoracic Society International Conference; H-46; San Diego 2013.
45. Vidaillac C., Leonard S.N., Rybak M.J. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob Agents Chemother 2009, 53:4712-4717.
46. Werth B.J., Sakoulas G., Rose W.E., Pogliano J., Tewhey R., Rybak M.J. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2013, 57:66-73.
47. Wilcox M.H., Corey G.R., Talbot G.H., Thye D., Friedland D., Baculik T. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010, 65(Suppl. 4):iv53-iv65.